Terumo (OTCMKTS:TRUMY – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06), Zacks reports. The firm had revenue of $1.96 billion during the quarter, compared to the consensus estimate of $1.94 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%.
Terumo Trading Down 4.8%
Shares of TRUMY traded down $0.76 on Friday, reaching $15.02. 3,220 shares of the company’s stock were exchanged, compared to its average volume of 233,917. The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $22.16 billion, a P/E ratio of 21.15 and a beta of 0.82. The business has a 50 day moving average price of $14.81 and a two-hundred day moving average price of $14.08. Terumo has a 12 month low of $12.08 and a 12 month high of $16.81.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the company. Nomura upgraded Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Two research analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy”.
View Our Latest Stock Report on TRUMY
Terumo Company Profile
Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.
Read More
- Five stocks we like better than Terumo
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
